---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-004094"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2026-06-12T20:01:17+00:00"
generated_at: "2026-06-12T20:02:56.771504+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Corvus stockholders re-elect Miller, Grais; ratify PwC as FY 2026 auditor

## Summary
- Richard A. Miller and Linda S. Grais elected as Class I directors with 58.3M and 53.2M votes for, respectively; 12.0M broker non-votes.
- Ratification of PricewaterhouseCoopers as independent auditor: 72.9M for, 105.7k against, 51.8k abstain.
- Non-binding advisory approval of NEO compensation: 58.9M for, 1.97M against, 64.3k abstain; 12.0M broker non-votes.
- 73.0M shares voted out of 84.1M shares outstanding as of record date April 16, 2026.

## SEC filing metadata
- accession: 0001171843-26-004094
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2026-06-12T20:01:17+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184326004094/0001171843-26-004094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184326004094/f8k_061226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-004094
- JSON: https://secwatch.observer/filing/0001171843-26-004094.json
- Plain text: https://secwatch.observer/filing/0001171843-26-004094.txt

## Key facts
- Shareholder Votes
  Corvus Pharmaceuticals, Inc. shareholders approved Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-11 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers On a non-binding advisory basis, the Company’s stockholders approved the compensation of the Company’s named executive officers. Votes For Votes Against Abstain Broker Non-Votes 58,936,532 1,971,370 64,329 12,049,623
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184326004094/0001171843-26-004094-index.htm
- Shareholder Votes
  Corvus Pharmaceuticals, Inc. shareholders approved Election of Class I Directors at the 2026-06-11 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal No. 1 — Election of Directors The Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until his or her respective successor is elected and qualified or appointed, or the earlier of his or her death, resignation or removal. Class III Director Nominees Votes For Votes Withheld Broker Non - Votes Richard A. Miller, M.D. 58,275,179 2,697,052 12,049,623 Linda S. Grais, M.D., J.D. 53,185,380 7,786,851 12,049,623
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184326004094/0001171843-26-004094-index.htm
- Shareholder Votes
  Corvus Pharmaceuticals, Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm at the 2026-06-11 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. Votes For Votes Against Abstain 72,864,335 105,674 51,845
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184326004094/0001171843-26-004094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.